Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158927 | 0.99 | MAPK1 (0.55) | MAPK1NAAACDK1EGLN2EGLN1 | |
| SCHEMBL13523836 | 0.86 | NAAA (0.56) | NAAACDK1ALDH1A1KDM4EHDAC3 | |
| SCHEMBL11038520 | 0.84 | NAAA (0.72) | MAPK1NAAACDK1ALDH1A1CYP1A2 | |
| SCHEMBL5655974 | 0.84 | NAAA (0.72) | MAPK1NAAACDK1ALDH1A1CYP1A2 | |
| SCHEMBL7743414 | 0.83 | HDAC3 (0.55) | MAPK1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4622847 | 0.83 | CDK1 (0.72) | MAPK1NAAACDK1CYP1A2CYP2C9 | |
| SCHEMBL29036025 | 0.82 | MAPK1 (0.63) | MAPK1NAAACDK1ALDH1A1CYP1A2 | |
| SCHEMBL2158919 | 0.82 | ALDH1A1 (0.64) | MAPK1NAAACDK1ALDH1A1CYP1A2 | |
| SCHEMBL2164508 | 0.82 | NAAA (0.57) | MAPK1NAAACDK1ALDH1A1CYP1A2 | |
| SCHEMBL31661686 | 0.82 | NAAA (0.57) | MAPK1NAAACDK1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| EP-1972349-A1 | GLP-1 fusion peptides conjugated to polymer(s), their production and use | Biocompatibles UK Limited (GB) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016229-A1 | Oral GLP-1 Formulations | GLP1R, GIPR, GCGR | MAPK1 1776/4885NAAA 1371/4885CDK1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.